Component

Cyclic pyranopterin monophosphate / cPMP

Cyclic pyranopterin monophosphate / cPMP. Species, exposure and limitations are retained in each linked claim.

6 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What it acts on

  1. Despite fosdenopterin within ten minutes of birth, the infant developed early seizures and retained motor impairment; seizures resolved and cognition was relatively spared.

    Cyclic pyranopterin monophosphate / cPMP → Neurological outcome in molybdenum cofactor deficiency source_derived_draftungraded
    Experimental context and source evidence
    availability_state
    machinery_impairment Imported condition classification; unverified.
    evidence_span
    {"source_cache": "artifacts/molybdenum-research/40429556.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "25a9bcc9dc74084f82ec89ca2850ea25ee8ae156c6650d69ccd460d66d02e1d1", "start_char": 0, "end_char": 1369, "text_sha256": "25a9bcc9dc74084f82ec89ca2850ea25ee8ae156c6650d69ccd460d66d02e1d1"}
    experimental_model
    Prenatally diagnosed MoCD-A single case with immediate neonatal fosdenopterin
    exposure
    Delivery at 32 weeks 6 days; drug within 10 minutes of birth
    limitations
    One case. Residual injury suggests prenatal disease, but does not prove efficacy or safety of fetal treatment.
    nutrient_topic
    Molybdenum research collection; topical membership is not evidence of a direct dietary effect. · Molybdenum
    organism
    Homo sapiens
    plain_language
    Even rapid replacement may not undo injury that began before birth.
    primary_references
    [mo-p40429556] Early Neonatal Fosdenopterin Treatment for Molybdenum Cofactor Deficiency Type A: New Insights into Its Natural History and Potential Role for Fetal Therapy. (2025). https://pubmed.ncbi.nlm.nih.gov/40429556/ DOI: 10.3390/jcm14103561
    tissue_or_cell_type
    Fetal/neonatal brain and follow-up to 24 months
    trigger_kind
    machinery_impairment Imported condition classification; unverified.

    Molybdenum: cofactor assembly, sulfur metabolism and nutrient interactions (2026-09-17) · lines 1210–1221

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Prenatally diagnosed MoCD-A single case with immediate neonatal fosdenopterin · source_derived_draft · unverified_draft

    ### mo-cpmp-early-limit Despite fosdenopterin within ten minutes of birth, the infant developed early seizures and retained motor impairment; seizures resolved and cognition was relatively spared. Condition category: machinery_impairment nutrient_topic: Molybdenum research collection; topical membership is not evidence of a direct dietary effect. plain_language: Even rapid replacement may not undo injury that began before birth. organism: Homo sapiens tissue_or_cell_type: Fetal/neonatal brain and follow-up to 24 months experimental_model: Prenatally diagnosed MoCD-A single case with immediate neonatal fosdenopterin limitations: One case. Residual injury suggests prenatal disease, but does not prove efficacy or safety of fetal treatment. exposure: Delivery at 32 weeks 6 days; drug within 10 minutes of birth evidence_span: {"source_cache": "artifacts/molybdenum-research/40429556.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "25a9bcc9dc74084f82ec89ca2850ea25ee8ae156c6650d69ccd460d66d02e1d1", "start_char": 0, "end_char": 1369, "text_sha256": "25a9bcc9dc74084f82ec89ca2850ea25ee8ae156c6650d69ccd460d66d02e1d1"} [mo-p40429556] Early Neonatal Fosdenopterin Treatment for Molybdenum Cofactor Deficiency Type A: New Insights into Its Natural History and Potential Role for Fetal Therapy. (2025). https://pubmed.ncbi.nlm.nih.gov/40429556/ DOI: 10.3390/jcm14103561
    Complete structured claim and evidence

  2. Urinary S-sulfocysteine, xanthine and urate approached normal within two days in all 11 MoCD-A patients receiving cPMP; eight rapidly improved clinically.

    Cyclic pyranopterin monophosphate / cPMP → Combined sulfur and purine biomarker pattern in Moco deficiency source_derived_draftungraded
    Experimental context and source evidence
    availability_state
    machinery_impairment Imported condition classification; unverified.
    evidence_span
    {"source_cache": "artifacts/molybdenum-research/26343839.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "2ad559ea27a88eb8d55c30c517ca0ca53d01125912e43a330ed1290f37aff3ad", "start_char": 0, "end_char": 2265, "text_sha256": "2ad559ea27a88eb8d55c30c517ca0ca53d01125912e43a330ed1290f37aff3ad"}
    experimental_model
    Prospective compassionate-use observational cohort of 16 neonates
    exposure
    cPMP replacement in 11 type A and five type B patients
    limitations
    Nonrandomized rare-disease cohort. Precursor replacement bypasses a specific biosynthetic step; it is not ordinary mineral supplementation.
    nutrient_topic
    Molybdenum research collection; topical membership is not evidence of a direct dietary effect. · Molybdenum
    organism
    Homo sapiens
    plain_language
    Supplying the missing precursor can bypass the first assembly block.
    primary_references
    [mo-p26343839] Efficacy and safety of cyclic pyranopterin monophosphate substitution in severe molybdenum cofactor deficiency type A: a prospective cohort study. (2015). https://pubmed.ncbi.nlm.nih.gov/26343839/ DOI: 10.1016/s0140-6736(15)00124-5
    tissue_or_cell_type
    MoCD biochemical markers and neurological outcomes
    trigger_kind
    machinery_impairment Imported condition classification; unverified.

    Molybdenum: cofactor assembly, sulfur metabolism and nutrient interactions (2026-09-17) · lines 1184–1195

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Prospective compassionate-use observational cohort of 16 neonates · source_derived_draft · unverified_draft

    ### mo-cpmp-type-a Urinary S-sulfocysteine, xanthine and urate approached normal within two days in all 11 MoCD-A patients receiving cPMP; eight rapidly improved clinically. Condition category: machinery_impairment nutrient_topic: Molybdenum research collection; topical membership is not evidence of a direct dietary effect. plain_language: Supplying the missing precursor can bypass the first assembly block. organism: Homo sapiens tissue_or_cell_type: MoCD biochemical markers and neurological outcomes experimental_model: Prospective compassionate-use observational cohort of 16 neonates limitations: Nonrandomized rare-disease cohort. Precursor replacement bypasses a specific biosynthetic step; it is not ordinary mineral supplementation. exposure: cPMP replacement in 11 type A and five type B patients evidence_span: {"source_cache": "artifacts/molybdenum-research/26343839.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "2ad559ea27a88eb8d55c30c517ca0ca53d01125912e43a330ed1290f37aff3ad", "start_char": 0, "end_char": 2265, "text_sha256": "2ad559ea27a88eb8d55c30c517ca0ca53d01125912e43a330ed1290f37aff3ad"} [mo-p26343839] Efficacy and safety of cyclic pyranopterin monophosphate substitution in severe molybdenum cofactor deficiency type A: a prospective cohort study. (2015). https://pubmed.ncbi.nlm.nih.gov/26343839/ DOI: 10.1016/s0140-6736(15)00124-5
    Complete structured claim and evidence

  3. The five MoCD-B patients showed no biochemical or clinical response to cPMP.

    Cyclic pyranopterin monophosphate / cPMP → Combined sulfur and purine biomarker pattern in Moco deficiency source_derived_draftungraded
    Experimental context and source evidence
    availability_state
    machinery_impairment Imported condition classification; unverified.
    evidence_span
    {"source_cache": "artifacts/molybdenum-research/26343839.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "2ad559ea27a88eb8d55c30c517ca0ca53d01125912e43a330ed1290f37aff3ad", "start_char": 0, "end_char": 2265, "text_sha256": "2ad559ea27a88eb8d55c30c517ca0ca53d01125912e43a330ed1290f37aff3ad"}
    experimental_model
    Prospective compassionate-use observational cohort of 16 neonates
    exposure
    cPMP replacement in 11 type A and five type B patients
    limitations
    Nonrandomized rare-disease cohort. Precursor replacement bypasses a specific biosynthetic step; it is not ordinary mineral supplementation.
    nutrient_topic
    Molybdenum research collection; topical membership is not evidence of a direct dietary effect. · Molybdenum
    organism
    Homo sapiens
    plain_language
    Supplying an upstream precursor cannot repair a broken downstream step.
    primary_references
    [mo-p26343839] Efficacy and safety of cyclic pyranopterin monophosphate substitution in severe molybdenum cofactor deficiency type A: a prospective cohort study. (2015). https://pubmed.ncbi.nlm.nih.gov/26343839/ DOI: 10.1016/s0140-6736(15)00124-5
    tissue_or_cell_type
    MoCD biochemical markers and neurological outcomes
    trigger_kind
    machinery_impairment Imported condition classification; unverified.

    Molybdenum: cofactor assembly, sulfur metabolism and nutrient interactions (2026-09-17) · lines 1197–1208

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Prospective compassionate-use observational cohort of 16 neonates · source_derived_draft · unverified_draft

    ### mo-cpmp-type-b The five MoCD-B patients showed no biochemical or clinical response to cPMP. Condition category: machinery_impairment nutrient_topic: Molybdenum research collection; topical membership is not evidence of a direct dietary effect. plain_language: Supplying an upstream precursor cannot repair a broken downstream step. organism: Homo sapiens tissue_or_cell_type: MoCD biochemical markers and neurological outcomes experimental_model: Prospective compassionate-use observational cohort of 16 neonates limitations: Nonrandomized rare-disease cohort. Precursor replacement bypasses a specific biosynthetic step; it is not ordinary mineral supplementation. exposure: cPMP replacement in 11 type A and five type B patients evidence_span: {"source_cache": "artifacts/molybdenum-research/26343839.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "2ad559ea27a88eb8d55c30c517ca0ca53d01125912e43a330ed1290f37aff3ad", "start_char": 0, "end_char": 2265, "text_sha256": "2ad559ea27a88eb8d55c30c517ca0ca53d01125912e43a330ed1290f37aff3ad"} [mo-p26343839] Efficacy and safety of cyclic pyranopterin monophosphate substitution in severe molybdenum cofactor deficiency type A: a prospective cohort study. (2015). https://pubmed.ncbi.nlm.nih.gov/26343839/ DOI: 10.1016/s0140-6736(15)00124-5
    Complete structured claim and evidence

What acts on it

  1. MOCS1A and MOCS1B jointly support conversion of GTP to cPMP, the first intermediate of human Moco synthesis.

    Human MOCS1A-MOCS1B cPMP synthesis system → Cyclic pyranopterin monophosphate / cPMP source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/molybdenum-research/31996372.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "a88a2e2c4aae83293fa6f1860d10bb41b41c32d1ad79b0b04cd5dd3eb02865c7", "start_char": 0, "end_char": 1846, "text_sha256": "a88a2e2c4aae83293fa6f1860d10bb41b41c32d1ad79b0b04cd5dd3eb02865c7"}
    experimental_model
    Alternative splicing, fluorescence microscopy, fractionation and mitochondrial targeting of human MOCS1 proteins
    exposure
    Type I-III MOCS1 splice constructs
    limitations
    Localization and processing experiments; no dietary iron, SAM or molybdenum intervention.
    nutrient_topic
    Molybdenum research collection; topical membership is not evidence of a direct dietary effect. · Molybdenum
    organism
    Homo sapiens
    plain_language
    The cofactor scaffold is built from GTP before molybdenum is inserted.
    primary_references
    [mo-p31996372] Alternative splicing of the bicistronic gene molybdenum cofactor synthesis 1 (MOCS1) uncovers a novel mitochondrial protein maturation mechanism. (2020). https://pubmed.ncbi.nlm.nih.gov/31996372/ DOI: 10.1074/jbc.ra119.010720
    tissue_or_cell_type
    Transfected human-cell localization and mitochondrial matrix

    Molybdenum: cofactor assembly, sulfur metabolism and nutrient interactions (2026-09-17) · lines 274–285

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Alternative splicing, fluorescence microscopy, fractionation and mitochondrial targeting of human MOCS1 proteins · source_derived_draft · unverified_draft

    ### mo-mocs1-cpmp MOCS1A and MOCS1B jointly support conversion of GTP to cPMP, the first intermediate of human Moco synthesis. Condition category: normal nutrient_topic: Molybdenum research collection; topical membership is not evidence of a direct dietary effect. plain_language: The cofactor scaffold is built from GTP before molybdenum is inserted. organism: Homo sapiens tissue_or_cell_type: Transfected human-cell localization and mitochondrial matrix experimental_model: Alternative splicing, fluorescence microscopy, fractionation and mitochondrial targeting of human MOCS1 proteins limitations: Localization and processing experiments; no dietary iron, SAM or molybdenum intervention. exposure: Type I-III MOCS1 splice constructs evidence_span: {"source_cache": "artifacts/molybdenum-research/31996372.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "a88a2e2c4aae83293fa6f1860d10bb41b41c32d1ad79b0b04cd5dd3eb02865c7", "start_char": 0, "end_char": 1846, "text_sha256": "a88a2e2c4aae83293fa6f1860d10bb41b41c32d1ad79b0b04cd5dd3eb02865c7"} [mo-p31996372] Alternative splicing of the bicistronic gene molybdenum cofactor synthesis 1 (MOCS1) uncovers a novel mitochondrial protein maturation mechanism. (2020). https://pubmed.ncbi.nlm.nih.gov/31996372/ DOI: 10.1074/jbc.ra119.010720
    Complete structured claim and evidence

  2. MOCS2B Glu168Lys attenuated binding of precursor Z/cPMP.

    Human MOCS2B p.Glu168Lys → Cyclic pyranopterin monophosphate / cPMP source_derived_draftungraded
    Experimental context and source evidence
    availability_state
    machinery_impairment Imported condition classification; unverified.
    evidence_span
    {"source_cache": "artifacts/molybdenum-research/12732628.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "154da4e4528674556bef92dfe50f098cfd9ae715c06ea01fc17d64c64b8aa319", "start_char": 0, "end_char": 1322, "text_sha256": "154da4e4528674556bef92dfe50f098cfd9ae715c06ea01fc17d64c64b8aa319"}
    experimental_model
    Purified human MPT synthase and patient-derived point mutants
    exposure
    Precursor Z/cPMP conversion assays
    limitations
    In-vitro assembly and kinetic defects; severity comparisons refer to specific patients, not a universal hierarchy.
    nutrient_topic
    Molybdenum research collection; topical membership is not evidence of a direct dietary effect. · Molybdenum
    organism
    Human proteins expressed in Escherichia coli
    plain_language
    A different mutation disrupts capture of the precursor.
    primary_references
    [mo-p12732628] Mechanistic studies of human molybdopterin synthase reaction and characterization of mutants identified in group B patients of molybdenum cofactor deficiency. (2003). https://pubmed.ncbi.nlm.nih.gov/12732628/ DOI: 10.1074/jbc.m303092200
    tissue_or_cell_type
    Reconstituted MOCS2A/MOCS2B tetramers
    trigger_kind
    machinery_impairment Imported condition classification; unverified.

    Molybdenum: cofactor assembly, sulfur metabolism and nutrient interactions (2026-09-17) · lines 430–441

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Purified human MPT synthase and patient-derived point mutants · source_derived_draft · unverified_draft

    ### mo-mocs2b-e168k MOCS2B Glu168Lys attenuated binding of precursor Z/cPMP. Condition category: machinery_impairment nutrient_topic: Molybdenum research collection; topical membership is not evidence of a direct dietary effect. plain_language: A different mutation disrupts capture of the precursor. organism: Human proteins expressed in Escherichia coli tissue_or_cell_type: Reconstituted MOCS2A/MOCS2B tetramers experimental_model: Purified human MPT synthase and patient-derived point mutants limitations: In-vitro assembly and kinetic defects; severity comparisons refer to specific patients, not a universal hierarchy. exposure: Precursor Z/cPMP conversion assays evidence_span: {"source_cache": "artifacts/molybdenum-research/12732628.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "154da4e4528674556bef92dfe50f098cfd9ae715c06ea01fc17d64c64b8aa319", "start_char": 0, "end_char": 1322, "text_sha256": "154da4e4528674556bef92dfe50f098cfd9ae715c06ea01fc17d64c64b8aa319"} [mo-p12732628] Mechanistic studies of human molybdopterin synthase reaction and characterization of mutants identified in group B patients of molybdenum cofactor deficiency. (2003). https://pubmed.ncbi.nlm.nih.gov/12732628/ DOI: 10.1074/jbc.m303092200
    Complete structured claim and evidence

  3. Human MOCS2A and MOCS2B assemble as active MPT synthase and convert cPMP to molybdopterin.

    Human MOCS2A-MOCS2B molybdopterin synthase → Cyclic pyranopterin monophosphate / cPMP source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/molybdenum-research/12732628.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "154da4e4528674556bef92dfe50f098cfd9ae715c06ea01fc17d64c64b8aa319", "start_char": 0, "end_char": 1322, "text_sha256": "154da4e4528674556bef92dfe50f098cfd9ae715c06ea01fc17d64c64b8aa319"}
    experimental_model
    Purified human MPT synthase and patient-derived point mutants
    exposure
    Precursor Z/cPMP conversion assays
    limitations
    In-vitro assembly and kinetic defects; severity comparisons refer to specific patients, not a universal hierarchy.
    nutrient_topic
    Molybdenum research collection; topical membership is not evidence of a direct dietary effect. · Molybdenum
    organism
    Human proteins expressed in Escherichia coli
    plain_language
    Two sulfur atoms create the part of the scaffold that will hold molybdenum.
    primary_references
    [mo-p12732628] Mechanistic studies of human molybdopterin synthase reaction and characterization of mutants identified in group B patients of molybdenum cofactor deficiency. (2003). https://pubmed.ncbi.nlm.nih.gov/12732628/ DOI: 10.1074/jbc.m303092200
    tissue_or_cell_type
    Reconstituted MOCS2A/MOCS2B tetramers

    Molybdenum: cofactor assembly, sulfur metabolism and nutrient interactions (2026-09-17) · lines 391–402

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Purified human MPT synthase and patient-derived point mutants · source_derived_draft · unverified_draft

    ### mo-mpt-synthase Human MOCS2A and MOCS2B assemble as active MPT synthase and convert cPMP to molybdopterin. Condition category: normal nutrient_topic: Molybdenum research collection; topical membership is not evidence of a direct dietary effect. plain_language: Two sulfur atoms create the part of the scaffold that will hold molybdenum. organism: Human proteins expressed in Escherichia coli tissue_or_cell_type: Reconstituted MOCS2A/MOCS2B tetramers experimental_model: Purified human MPT synthase and patient-derived point mutants limitations: In-vitro assembly and kinetic defects; severity comparisons refer to specific patients, not a universal hierarchy. exposure: Precursor Z/cPMP conversion assays evidence_span: {"source_cache": "artifacts/molybdenum-research/12732628.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "154da4e4528674556bef92dfe50f098cfd9ae715c06ea01fc17d64c64b8aa319", "start_char": 0, "end_char": 1322, "text_sha256": "154da4e4528674556bef92dfe50f098cfd9ae715c06ea01fc17d64c64b8aa319"} [mo-p12732628] Mechanistic studies of human molybdopterin synthase reaction and characterization of mutants identified in group B patients of molybdenum cofactor deficiency. (2003). https://pubmed.ncbi.nlm.nih.gov/12732628/ DOI: 10.1074/jbc.m303092200
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards